Equities researchers at StockNews.com initiated coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the stock.
Separately, Alliance Global Partners upped their price target on shares of Tonix Pharmaceuticals from $6.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, July 22nd.
Read Our Latest Stock Analysis on Tonix Pharmaceuticals
Tonix Pharmaceuticals Trading Down 2.1 %
Institutional Inflows and Outflows
An institutional investor recently raised its position in Tonix Pharmaceuticals stock. Acadian Asset Management LLC grew its holdings in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Free Report) by 260.6% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 335,373 shares of the company’s stock after acquiring an additional 242,358 shares during the quarter. Acadian Asset Management LLC owned 0.40% of Tonix Pharmaceuticals worth $61,000 as of its most recent SEC filing. 82.26% of the stock is owned by institutional investors and hedge funds.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Recommended Stories
- Five stocks we like better than Tonix Pharmaceuticals
- How to Calculate Stock Profit
- This Small Cap Wealth Management Stock Could Provide Big Returns
- Short Selling: How to Short a Stock
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- What Is WallStreetBets and What Stocks Are They Targeting?
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.